VTE and anti-coagulation therapy in cancer patients

Eur Heart J Cardiovasc Pharmacother. 2019 Oct 1;5(4):189-191. doi: 10.1093/ehjcvp/pvz027.

Authors

Yusuke Miyazaki^{1

2

3}, Kazuhiro Sase^{2

4}, Koji Hasegawa^{1

2}, Tatsuya Morimoto^{1

2

3}

Affiliations

¹ Division of Molecular Medicine, School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka, Japan.
² Division of Translational Research, National Hospital Organization Kyoto Medical Center, Kyoto, Japan.
³ Shizuoka General Hospital, Shizuoka, Japan.
⁴ Clinical Pharmacology and Regulatory Science, Juntendo University Medical School, Tokyo, Japan.

PMID: 31378809
DOI: 10.1093/ehjcvp/pvz027

No abstract available

Publication types

Editorial

MeSH terms

Anticoagulants / adverse effects
Anticoagulants / therapeutic use*
Blood Coagulation / drug effects*
Clinical Trials as Topic
Dalteparin / adverse effects
Dalteparin / therapeutic use*
Factor Xa Inhibitors / adverse effects
Factor Xa Inhibitors / therapeutic use*
Humans
Neoplasms / blood*
Neoplasms / diagnosis
Neoplasms / epidemiology
Pyridines / adverse effects
Pyridines / therapeutic use*
Recurrence
Risk Factors
Secondary Prevention
Thiazoles / adverse effects
Thiazoles / therapeutic use*
Treatment Outcome
Venous Thromboembolism / blood
Venous Thromboembolism / diagnosis
Venous Thromboembolism / drug therapy*
Venous Thromboembolism / epidemiology

Substances

Anticoagulants
Factor Xa Inhibitors
Pyridines
Thiazoles
edoxaban
Dalteparin